Email this article Benefits of capecitabine in hormone receptor-positive compared to hormone receptor-negative breast cancer
- Issue: Vol 24, No 2 (2022)
- Pages: 253-253
- Section: CLINICAL ONCOLOGY
- URL: https://ogarev-online.ru/1815-1434/article/view/109354
- DOI: https://doi.org/10.26442/18151434.2022.2.201727
- ID: 109354
Cite item
Full Text
Abstract
This publication is the Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review: Siao-Nge Hoon, Peter K H Lau, Alison M White, Max K Bulsara, Patricia D Banks, Andrew D Redfern. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. Version published: 26 May 2021. DOI: 10.1002/14651858.CD011220.pub2
Full Text
##article.viewOnOriginalSite##Supplementary files
